RS-2025-25454827

Phase 2 study of Oral VVZ-2471 for the treatment of chronic neuropathic pain

Vivozon, Inc.

VIVOZON

NEUROLOGY	Phase 2

Product Type	Small molecule
Indication	Chronic neuropathic pain
Target	Two G-Protein Coupled Receptors - 5-HT2AR and mGluR5
MoA(Mechanism of Action)	Enhanced anti-nociceptive efficacy via simultaneous dual antagonism against 5-HT2AR and mGluR5
Competitiveness	1) Innovative **first-in-class** oral dual-acting analgesic targeting both 5-HT2A and mGluR5 receptors, offering a novel mechanism distinct from existing ion-channel or opioid-related analgesics. 2) Demonstrated **potent anti-nociceptive efficacy comparable to morphine and gabapentin** in multiple neuropathic and inflammatory pain models, without tolerance, dependence, or abuse liability. 3) **Synergistic dual antagonism** provides enhanced analgesic efficacy with significantly reduced CNS and cardiovascular side effects, overcoming the major limitations of current neuropathic pain therapies. 4) **Low potential for drug–drug interactions** (no CYP450 or transporter inhibition) enables safe **stand-alone use or combination therapy** with opioids, gabapentinoids, or antidepressants. 5) Exhibits **unique prophylactic and therapeutic effects on opioid dependence and relapse**, positioning VVZ-2471 as a transformative candidate bridging pain management and addiction treatment. 6) Strong IP protection with **composition-of-matter and method-of-use patents** secured or pending in major global territories (US, CN, EU, JP, etc.). 7) Potential to **expand indications** to diabetic neuropathy, postherpetic neuralgia, cancer pain, and acute pain conditions, offering broad clinical and commercial scalability.
Development Stage	Phase 2
Route of Administration	Per Oral